All In Biotech

Drug Trial Radar · NCT01743651

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Nov 2012

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
RVL Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Osmotica Pharmaceutical US LLC
First posted
Dec 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity. Eligible subjects will be removed from anti-spasticity medications for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks.

Conditions

  • Spasticity
  • Multiple Sclerosis

Interventions

  • arbaclofenDrug

    40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day

  • baclofenDrug

    80 mg/day as 20 mg baclofen administered orally 4 times per day

  • PlaceboDrug

    arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb.Time frame: Change in baseline from Visit 1 through Visit 9 (120 days) or end of treatment
  2. Clinical Global Impression of Change (CGIC) through end of treatmentTime frame: Visit 9 (120 days) or end of study

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • Osmotica Study Site-138

    Cullman, Alabama

  • Osmotica Site-143

    Long Beach, California

  • Osmotica Study Site-123

    Aurora, Colorado

  • Osmotica Study Site-110

    Bradenton, Florida

  • Osmotica Study Site-142

    Maitland, Florida

  • Osmotica Study Site-119

    Ormond Beach, Florida

  • Osmotica Study Site-120

    Pompano Beach, Florida

  • Osmotica Study Site-109

    Tampa, Florida

  • Osmotica Study Site-126

    Northbrook, Illinois

  • Osmotica Study Site-108

    Fort Wayne, Indiana

  • Osmotica Study Site-116

    Lenexa, Kansas

  • Osmotica Study Site-124

    Baltimore, Maryland

  • Osmotica Study Site-136

    Springfield, Massachusetts

  • Osmotica Study Site-101

    Ann Arbor, Michigan

  • Osmotica Study Site-115

    Johnson City, New York

  • Osmotica Study Site-113

    New York, New York

  • Osmotica Study Site-141

    New York, New York

  • Osmotica Study Site-125

    New York, New York

  • Osmotica Study Site-106

    Charlotte, North Carolina

  • Osmotica Study Site-131

    Cincinnati, Ohio

  • Osmotica Study Site-127

    Pittsburgh, Pennsylvania

  • Osmotica Study Site-112

    San Antonio, Texas

  • Osmotica Study Site-133

    Salt Lake City, Utah

  • Osmotica Study Site-129

    Seattle, Washington

  • Osmotica SIte-144

    Tacoma, Washington

  • Osmotica Site-511

    Krasnoyarsk, Russia

  • Osmotica Study Site-508

    Krasnoyarsk, Russia

  • Osmotica Study Site-510

    Krasnoyarsk, Russia

  • Osmotica Study Site-501

    Moscow, Russia

  • Osmotica Study Site-502

    Moscow, Russia

  • Osmotica Study Site-503

    Saint Petersburg, Russia

  • Osmotica Study Site-505

    Saint Petersburg, Russia

  • Osmotica Study Site-507

    Saint Petersburg, Russia

  • Osmotica Study Site-506

    Sestroretsk, Russia

  • Osmotica Study Site-509

    Pyatigorsk, Stavropol Kray, Russia

  • Osmotica Study Site-510

    Tonnel’nyy, Stavropol Kray, Russia

  • Osmotica Study Site 614

    Chernihiv, Ukraine

  • Osmotica Study Site-602

    Dnipropetrovsk, Ukraine

  • Osmotica Study Site-603

    Dnipropetrovsk, Ukraine

  • Osmotica Study Site-609

    Dnipropetrovsk, Ukraine

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.